BETA-2 MICROGLOBULIN LEVEL AS AN INDICATOR OF PROGNOSIS IN DIFFUSE LARGE CELL LYMPHOMA

被引：18

作者：

AVILES, A ^{[1
]}

ZEPEDA, G ^{[1
]}

DIAZMAQUEO, JC ^{[1
]}

RODRIGUEZ, L ^{[1
]}

GUZMAN, R ^{[1
]}

GARCIA, EL ^{[1
]}

TALAVERA, A ^{[1
]}

机构：

[1] INST MEXICANO SEGURO SOCIAL,NATL MED CTR,HOSP ONCOL,DEPT HEMATOL,MEXICO CITY 7,DF,MEXICO

来源：

LEUKEMIA & LYMPHOMA | 1992年 / 7卷 / 1-2期

关键词：

BETA-2; MICROGLOBULIN; PROGNOSIS; DIFFUSE LARGE CELL NHL; LYMPHOMA;

D O I：

10.3109/10428199209053613

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We report results of our investigation of prognostic factors for patients with diffuse large cell lymphoma (DLCL) who were entered on the same treatment protocol and who had known pretreatment serum beta 2 microglobulin levels. Serum beta 2 microglobulin, bone marrow involvement, performance status and lactic dehydrogenase (LDH) levels were associated with a poor prognosis in univariate analysis. However, only beta 2 microglobulin remained of prognostic significance in a multivariate analysis with statistical differences at different cut off levels. We believe that beta 2 microglobulin levels accurately separate patients into low-, intermediate- and high-risk patients. It is concluded that serum beta 2 microglobulin is the most significant prognostic factor currently available for DLCL and should be incorporated in the initial staging in order to provide a basis for designing the therapeutic approach in these cases. © 1992 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.

引用

页码：135 / 138

页数：4

共 25 条

[1]

Epelbaum R., Fanaggi D., Ben-Arie Y., Et al., Survival of diffuse large cell lymphoma, Cancer, 66, pp. 1124-1129, (1990)

[2]

Vose J.M., Armitage J.D., Weisenburger D.D., Et al., The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma, J. Clin. Oncol., 6, pp. 1838-1844, (1988)

[3]

Coiffier B., Lepage E., Prognosis of aggressive lymphomas. A study of five prognostic models with patients included in the LNH-84 regimen, Blood, 74, pp. 558-564, (1989)

[4]

Aviles A., Diaz-Maqueo J.C., Rodriguez L., Et al., Group risk classification of non-Hodgkin's lymphoma, Arch. Invest. Med., 21, pp. 11-16

[5]

Armitage J.O., Dick F.R., Corder M.P., Garneau S.G., Platz C.E., Slymen D.J., Predicting therapeutic outcome in patients with diffuse histiocytic lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP), Cancer, 50, pp. 1695-1702, (1982)

[6]

Coiffier B., Shipp M.A., Cabanillas F., Crowther D., Armitage J.O., Canellos G.P., Report on the first workshop on prognostic factors in large-cell lymphoma, Ann Oncol., 2, pp. 213-217, (1991)

[7]

Swan F., Velasquez W.S., Tucker S., Et al., A new serologic staging system for large-cell lymphomas based on initial beta 2 microglobulin and lactate dehydrogenase levels, J. Clin. Omol, 7, pp. 1518-1527, (1989)

[8]

Simon R., Durrleman S., Hoppe R.T., Et al., Prognostic factors for patients with diffuse large-cell or immunoblastic non-Hodgkin's lymphomas. Experience of the Non-Hodgkin's Lymphoma Pathologic Classification Project, Med. Pediatr. Oncol., 18, pp. 89-96, (1990)

[9]

Velasquez W.S., Jagannath S., Tucker S.L., Et al., Risk classification as the basis for clinical staging of large-cell lymphoma derives from 10-year survival data, Blood, 74, pp. 552-557, (1989)

[10]

Shimoyama M., Ota K., Kikuchi M., Et al., Chemotherapeutic results and prognostic factors of patients with advanced non-Hodgkin's lymphoma treated with VEPA or VEPA-, J. Clin. Oncol., 6, pp. 128-141, (1988)

← 1 2 3 →